for Zepbound in just over a year, following the FDA approval for adults with obesity or overweight who also have weight-related medical problems in November 2023.
Each approach will come with different pros, cons, and levels of commitment
If enough Part D plans opt-in, this model will become the standard beginning January 2027
Unlike injectable GLP-1 receptor agonists (GLP-1RA), it offers the benefit of increased patient acceptance [2]
Strategic Advantages for B2B Procurement Lower Total Cost of Ownership (TCO) : Reusable pens, despite a potentially higher upfront cost, offer significant long-term savings compared to disposable alternatives, especially for chronic therapies
Reports cite patients accidentally overdosing , resulting in severe side effects like nausea and vomiting